Ricerca Biosciences has entered a strategic partnership with Fulcrum Pharma, an Aptiv Solutions company, to provide value-added capabilities to biopharma companies by creating a streamlined and efficient process to move a drug candidate from development to the clinic.

The collaboration will leverage Ricerca’s comprehensive preclinical services from early discovery medicinal chemistry, compound screening, profiling and lead optimization through full drug safety, metabolism and efficacy development support, as well as clinical supply and commercial API production. Fulcrum Pharma provides strategic and operational regulatory support to assist clients with regulatory submissions.

“The Fulcrum Pharma collaboration is an attractive and exciting proposition for Ricerca and our clients. Fulcrum Pharma brings deep experience in IND authorship and regulatory approval, which fits well with Ricerca’s preclinical services in discovery pharmacology, chemical development and drug safety assessment. The relationship greatly expands our ability to serve our clients who are preparing for regulatory submission anywhere in the world,” commented Ian Lennox, chief executive officer of Ricerca.

“The collaboration offers our early stage clients a streamlined service to move efficiently through preclinical development to creation of high quality IND submissions,” said Patrick K. Donnelly, Aptiv Solutions’ chairman and chief executive officer. “This approach, coupled with our expertise in adaptive clinical trial design, will provide our clients with the ability to accelerate the development of their products and stay ahead of the competition.”